[go: up one dir, main page]

WO2018136163A3 - Tandem apoa-1 fusion polypeptides - Google Patents

Tandem apoa-1 fusion polypeptides Download PDF

Info

Publication number
WO2018136163A3
WO2018136163A3 PCT/US2017/065078 US2017065078W WO2018136163A3 WO 2018136163 A3 WO2018136163 A3 WO 2018136163A3 US 2017065078 W US2017065078 W US 2017065078W WO 2018136163 A3 WO2018136163 A3 WO 2018136163A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion polypeptides
apoa
polypeptide
disclosed
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/065078
Other languages
French (fr)
Other versions
WO2018136163A2 (en
Inventor
Martha S. Hayden-Ledbetter
Jeffrey A. Ledbetter
Vince Montes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theripion Inc
Original Assignee
Theripion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theripion Inc filed Critical Theripion Inc
Publication of WO2018136163A2 publication Critical patent/WO2018136163A2/en
Publication of WO2018136163A3 publication Critical patent/WO2018136163A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. In particular embodiments, the fusion polypeptides include first and second polypeptide segments joined in tandem via a linker, each segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic. Fusion polypeptides may also include a dimerizing domain or domain that specifically binds the neonatal Fc receptor (e.g., an Fc region or albumin), which is typically linked carboxyl-terminal to the second polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes an additional polypeptide segment conferring a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithincholesterol acyltransferase, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides comprising a dimerizing domain as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.
PCT/US2017/065078 2016-12-09 2017-12-07 Tandem apoa-1 fusion polypeptides Ceased WO2018136163A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662432128P 2016-12-09 2016-12-09
US62/432,128 2016-12-09
US201762467288P 2017-03-06 2017-03-06
US62/467,288 2017-03-06

Publications (2)

Publication Number Publication Date
WO2018136163A2 WO2018136163A2 (en) 2018-07-26
WO2018136163A3 true WO2018136163A3 (en) 2018-09-27

Family

ID=62152610

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/065078 Ceased WO2018136163A2 (en) 2016-12-09 2017-12-07 Tandem apoa-1 fusion polypeptides

Country Status (1)

Country Link
WO (1) WO2018136163A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114578046A (en) * 2020-11-30 2022-06-03 广东菲鹏生物有限公司 Novel coronavirus (SARS-CoV-2) antibody detection reagent
CA3206901A1 (en) 2021-02-19 2022-08-25 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54046B1 (en) 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (en) 1984-12-06 1991-02-12 Jacques Oberto Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
JPH08502646A (en) 1992-09-14 1996-03-26 ファイザー・インコーポレイテッド Immortalized cells and their use
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5854039A (en) 1996-07-17 1998-12-29 Zymogenetics, Inc. Transformation of pichia methanolica
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2002094852A2 (en) 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
EP1664116A4 (en) 2003-08-22 2009-06-03 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20070111281A1 (en) 2005-05-09 2007-05-17 Glycart Biotechnology Ag Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
SG194680A1 (en) 2011-04-29 2013-12-30 Univ Washington Therapeutic nuclease compositions and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEGREST J P ET AL: "STRUCTURE AND FUNCTION OF APOLIPOPROTEIN A-I AND HIGH-DENSITY LIPOPROTEIN", CURRENT OPINION IN LIPIDO, LIPPINCOTT WILLIAMS AND WILKINS, LONDON, GB, vol. 11, no. 2, 1 April 2000 (2000-04-01), pages 105 - 115, XP009030702, ISSN: 0957-9672, DOI: 10.1097/00041433-200004000-00002 *
SHU-CHEN LU ET AL: "An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice", JOURNAL OF LIPID RESEARCH, vol. 53, no. 4, 1 April 2012 (2012-04-01), US, pages 643 - 652, XP055484725, ISSN: 0022-2275, DOI: 10.1194/jlr.M020438 *

Also Published As

Publication number Publication date
WO2018136163A2 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
EP2352523A4 (en) ANTI-CD19 ENHANCED ANTIBODIES
JO3658B1 (en) Fusion proteins
BR112021017399A2 (en) Bifunctional fusion protein and its pharmaceutical use
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX2022015847A (en) Cd123 binding proteins and related compositions and methods.
HK1200842A1 (en) Proteins with improved half-life and other properties
MX2018010824A (en) Inducible binding proteins and methods of use.
MX2015000397A (en) COMPACT OF FACTOR VIII WITH XTEN AND PROTEIN OF VON WILLEBRAND FACTOR, AND ITS USES.
WO2013003649A3 (en) Wap domain fusion polypeptides and methods of use thereof
PH12018502451A1 (en) Brain delivery protein
WO2006104677A3 (en) Antibodies that bind ov064 and methods of use therefor
MX2019009817A (en) Anti-tau antibodies and methods of use thereof.
WO2015175874A3 (en) Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
PL397167A1 (en) Anti-tumor fusion protein
MX350962B (en) Method for making antibody fc-heterodimeric molecules using electrostatic steering effects.
WO2015031673A3 (en) Cns-targetedconjugates of antibodies
MX388977B (en) INTERLEUKIN 2/INTERLEUKIN-2 ALPHA RECEPTOR FUSION PROTEINS AND METHODS OF USE.
WO2013181087A3 (en) Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
WO2007070671A3 (en) Therapeutic methods for inhibiting tumor growth with dll4 antagonists
EA201791238A1 (en) METHODS AND COMPOSITIONS IN WHICH OPTIONS OF KLOTHO POLYPEPTIDES ARE USED
MX389878B (en) CHIMERIC FACTOR VIII PROTEINS AND THEIR USES.
JP2017501728A5 (en)
BR112012006492A2 (en) multivalent antibody fusion protein, and albumin binding
MA38797A1 (en) Therapeutic fusion protein
BR112013020274A2 (en) post-translationally modified protein substitutes and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17870650

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17870650

Country of ref document: EP

Kind code of ref document: A2